Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug

Pharmaceutical Research

Volumn 32, Issue 4, 2015, Pages 1451-1461

  Zhang, Wenli ^a,b   Wang, Guangji ^b   Falconer, James R ^a   Baguley, Bruce C ^c   Shaw, John P ^a   Liu, Jianping ^b   Xu, Hongtao ^a   See, Esther ^a   Sun, Jianguo ^b   Aa, Jiye ^b   Wu, Zimei ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

active loading; cyclodextrin; liposomes; pharmacokinetics; supersaturated

Indexed keywords

ANTINEOPLASTIC AGENT; ASULACRINE ISETHIONATE; BETA CYCLODEXTRIN; DRUG CARRIER; GLUCOSE; LIPOSOME; AMMONIUM SULFATE; AMSACRINE; ASULACRINE; BETA CYCLODEXTRIN DERIVATIVE; SBE4-BETA-CYCLODEXTRIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATHETER; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIALYSIS; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUTION; DRUG UPTAKE; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMAL DELIVERY; LIPOSOME MEMBRANE; LOADING DRUG DOSE; NEW ZEALAND RABBIT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSMISSION ELECTRON MICROSCOPY; VOLUME OF DISTRIBUTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; RABBIT; SOLUBILITY;

AMMONIUM SULFATE; AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; DRUG CARRIERS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MOLECULAR STRUCTURE; RABBITS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84925463255     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1551-8     Document Type: Article

References (40)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release. 2000;65(1):271-84.
3. Taurin S, Nehoff H, Diong J, Larsen L, Rosengren RJ, Greish K. Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer. J Drug Target. 2013;21(7):675-83.
4. Xu H, Paxton J, Lim J, Li Y, Zhang W, Duxfield L, et al. Development of high-content gemcitabine pegylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Pharma Res. 2014;1-10.
5. Cui Y, Wu Z, Liu X, Ni R, Zhu X, Ma L, et al. Preparation, safety, pharmacokinetics, and pharmacodynamics of liposomes containing Brucea javanica oil. AAPS PharmSciTech. 2010;11(2):878-84.
6. Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv. 2011;8(5):565-80.
7. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, Barenholz Y, et al. Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligando liposomes. J Liposome Res. 1994;4(1):455-79.
8. Clerc S, Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta. 1995;1240(2):257-65.
9. Gubernator J, Chwastek G, Korycińska M, Stasiuk M, Grynkiewicz G, Lewrick F, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release. 2010;146(1):68-75.
10. Li C, Cui J, Wang C, Li Y, Zhang L, Xiu X, et al. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. J Pharm Pharmacol. 2011;63(6):765-73.
11. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, et al. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 2006;114(1):78-88.
12. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. J Control Release. 2009;139(1):73-80.
13. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152(2):253-8.
14. Modi S, Xiang T-X, Anderson BD. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. J Control Release. 2012;162(2):330-9.
15. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, et al. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Cancer Res. 1984;44(8):3245-51.
16. Schneider E, Darkin SJ, Lawson PA, Ching L-M, Ralph RK, Baguley BC. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino) ethyl] acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol. 1988;24(11):1783-90.
17. Fyfe D, Price C, Langley R, Pagonis C, Houghton J, Osborne L, et al. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 2001;47(4):333-7.
18. Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, et al. A phase II trial of CI-921 in advanced malignancies. Inves New Drugs. 1992;10(4):309-12.
19. See E, Zhang W, Liu J, Svirskis D, Baguley BC, Shaw JP, et al. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. Int J Pharm. 2014;473(1-2):528-35.
20. Yalkowsky SH, Valvani SC, Johnson BW. In vitro method for detecting precipitation of parenteral formulations after injection. J Pharma Sci. 1983;72(9):1014-7.
21. Wu Z, Hassan D, Shaw JP. In-vitro prediction of bioavailability following extravascular injection of poorly soluble drugs: an insight into clinical failure and the role of delivery systems. J Pharm Pharmacol. 2013;65(10):1429-39.
22. Powis G, Kovach JS. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. Cancer Res. 1983;43(2):925-9.
23. Hu K, Zhu L, Liang H, Hu F, Feng J. Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides. Arch Pharm Res. 2011;34(9):1487-94.
24. Liu X, Sun W, Zhang B, Tian B, Tang X, Qi N, et al. Clarithromycin-loaded liposomes offering high drug loading and less irritation. Int J Pharm. 2013;443(1):318-27.
25. Sriwongsitanont S, Ueno M. Effect of Freeze-Thawing Process on the Size and Lamellarity of PEG-Lipid Liposomes. Open Colloid Sci J. 2011;4:1-6.
26. Johnsson M, Edwards K. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly (ethylene glycol)-phospholipids. Biophys J. 2003;85(6):3839-47.
27. Taratula O, Dani RK, Schumann C, Xu H, Wang A, Song H, et al. Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells. Int J Pharm. 2013;458(1):169-80.
28. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758(10):1633-40.
29. Harrigan P, Wong K, Redelmeier T, Wheeler J, Cullis P. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta. 1993;1149(2):329-38.
30. Lee C-M, Choi Y, Huh EJ, Lee KY, Song H-C, Sun MJ, et al. Polyethylene Glycol (PEG) Modified 99mTc-HMPAOLiposome for Improving Blood Circulation and Biodistribution: The Effect of the Extent of PEGylation. Cancer Biother Radiopharm. 2005;20(6):620-8.
31. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA. Working PK, editors Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol. 2004;31:16-35.
32. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25-44.
33. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev. 2001;53(2):283-318.
34. Piel G, Piette M, Barillaro V, Castagne D, Evrard B, Delattre L. Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes. Int J Pharm. 2007;338(1):35-42.
35. Puskás I, Csempesz F. Influence of cyclodextrins on the physical stability of DPPC-liposomes. Colloids Surf B: Biointerfaces. 2007;58(2):218-24.
36. Lindner LH, Hossann M. Factors affecting drug release from liposomes. Expert Opin Drug Discov Devel. 2010;13(1):111-23.
37. Zhigaltsev IV, Maurer N, Akhong Q-F, Leone R, Leng E, Wang J, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release. 2005;104(1):103-11.
38. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta. 1999;1416(1):1-10.
39. Lasic D, Čeh B, Stuart M, Guo L, Frederik P, Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. Biochim Biophys Acta. 1995;1239(2):145-56.
40. Mady MM, Darwish MM. Effect of chitosan coating on the characteristics of DPPC liposomes. J Advanc Resb. 2010;1(3):187-91.